Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV

Share on twitter Share on linkedin SAN FRANCISCO, Sept. 15, 2021 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for EBT-101, a CRISPR-based therapeutic candidate in development as […]